Key result
In Japanese patients with non-valvular atrial fibrillation treated with rivaroxaban, renal dysfunction was associated with a significantly higher incidence of stroke or systemic embolism compared to normal renal function (1.47%/year vs. 0.85%/year).
Why the study?
This sub-analysis investigated the effectiveness and safety of rivaroxaban in Japanese NVAF patients based on baseline creatinine clearance levels and prescribed rivaroxaban doses.
Does inappropriate dosing of rivaroxaban affect the risk of stroke, bleeding, and mortality in Japanese patients with non-valvular atrial fibrillation and varying renal function?
Population
6806 Japanese NVAF patients with baseline CrCl data
Comparison
Dosing according to renal function (CrCl ≥ 50 mL/min vs CrCl < 50 mL/min)
Design
Observational sub-analysis with propensity score matching
Authors
Loading...
Inappropriate rivaroxaban dosing may raise mortality or bleeding risks by renal function; observational data leave causal effects open.
Observational (n=6,806)
Yes
Does inappropriate dosing of rivaroxaban affect the risk of stroke, bleeding, and mortality in Japanese patients with non-valvular atrial fibrillation and varying renal function?
Absolute Event Rate: 1.47% vs 0.85%
p-value: p=<0.001
Appropriate dose reduction of rivaroxaban based on renal function is crucial to balance the risks of bleeding and ischemia in patients with non-valvular atrial fibrillation.
Atarashi et al. (2021) conducted an observational in Non-valvular atrial fibrillation (n=6,806). Renal dysfunction (CrCl < 50 mL/min) vs. Normal renal function (CrCl ≥ 50 mL/min) was evaluated on Stroke or systemic embolism (p=<0.001). In Japanese patients with non-valvular atrial fibrillation treated with rivaroxaban, renal dysfunction was associated with a significantly higher incidence of stroke or systemic embolism compared to normal renal function (1.47%/year vs. 0.85%/year).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: